Marvel Biosciences Corp (TSE:MRVL)
:MRVL
Want to see TSE:MRVL full AI Analyst Report?
MRVL Stock Chart & Stats
C$0.14
-C$0.01(-6.45%)
At close: 4:00 PM EST
C$0.14
-C$0.01(-6.45%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.40
Previous CloseN/A
Volume5.00K
Average Volume (3M)89.38K
Market Cap
C$15.76M
Enterprise ValueC$11.49M
Total Cash (Recent Filing)C$274.17K
Total Debt (Recent Filing)C$2.31M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Jun 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding63,028,290
10 Day Avg. Volume75,294
30 Day Avg. Volume89,378
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Narrowing LossesYear-over-year narrowing of net losses suggests improved cost control and operating discipline. For an early-stage biotech this durable trend can extend runway, reduce near-term financing needs, and improve the company's ability to execute development milestones without immediate capital raises.
Improving Cash BurnA demonstrable reduction and stabilization in cash burn is a meaningful structural improvement. Sustained lower outflows extend runway, reduce frequency of dilutive financings, and give management more time to advance programs or partner, strengthening long-term capital efficiency.
Lean Operating StructureA very small headcount points to a capital-efficient, lean operating model typical of early-stage biotech. Lower fixed overhead supports longer runway per dollar raised and allows the company to allocate scarce resources to core R&D activities, preserving optionality.
Bears Say
Negative Shareholder EquityPersistently negative equity combined with notable debt constrains financial flexibility. It raises refinancing and covenant risk, increases the likelihood of dilutive equity raises, and limits the company’s ability to fund growth or absorb setbacks without material ownership dilution.
No RevenueAbsence of revenue leaves the firm fully dependent on external financing and partnerships to fund operations. This structural funding reliance magnifies execution risk: failure to secure capital or partners could curtail programs and materially impair long-term viability.
Weak Cash & Small Asset BaseNegative operating cash flow and a very small asset base limit resilience to delays or unexpected costs. Structural cash generation weakness increases probability of near-term fundraising, which can dilute shareholders and impede long-term R&D planning if markets or partners are inaccessible.
Marvel Biosciences Corp News
MRVL FAQ
What was Marvel Biosciences Corp’s price range in the past 12 months?
Marvel Biosciences Corp lowest stock price was C$0.09 and its highest was C$0.40 in the past 12 months.
What is Marvel Biosciences Corp’s market cap?
Marvel Biosciences Corp’s market cap is C$15.76M.
When is Marvel Biosciences Corp’s upcoming earnings report date?
Marvel Biosciences Corp’s upcoming earnings report date is Jun 23, 2026 which is in 18 days.
How were Marvel Biosciences Corp’s earnings last quarter?
Marvel Biosciences Corp released its earnings results on Mar 31, 2026. The company reported -C$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.005.
Is Marvel Biosciences Corp overvalued?
According to Wall Street analysts Marvel Biosciences Corp’s price is currently Overvalued.
Does Marvel Biosciences Corp pay dividends?
Marvel Biosciences Corp does not currently pay dividends.
What is Marvel Biosciences Corp’s EPS estimate?
Marvel Biosciences Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marvel Biosciences Corp have?
Marvel Biosciences Corp has 63,028,290 shares outstanding.
What happened to Marvel Biosciences Corp’s price movement after its last earnings report?
Marvel Biosciences Corp reported an EPS of -C$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Marvel Biosciences Corp?
Currently, no hedge funds are holding shares in TSE:MRVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marvel Biosciences Corp
Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.
Technical Analysis
BetterLife Pharma
―
―
Entheon Biomedical
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Options Prices
Currently, No data available
---